Lizardo AE, García-Reyna JC, García-Gómez J, Alva-López LF

Language: English
References: 26
Page: 74-81
PDF size: 197.06 Kb.

ABSTRACT

Cancer is one of the leading causes of morbidity and mortality in the world. Positron emission tomography (PET) - computed tomography (CT) is a unique combination of the cross-sectional anatomic information provided by CT and the metabolic information provided by PET, which are acquired during a single examination and fused. PET-CT imaging is frequently requested in oncology, neurology and cardiology. Radiologists and nuclear medicine physicians are often asked to perform a panel of imaging examinations as part of the initial staging or follow-up of cancer patients. The use of specific radiopharmaceuticals for imaging organ function and disease states is a unique capability of nuclear medicine. The vast majority of PET radiopharmaceuticals today are produced in a cyclotron. Medical imaging must, therefore, integrate polyvalent skills enabling imaging specialists to understand and interpret all types of images. Complex clinical decisions about treatment of oncologic patients are largely guided by imaging findings, among other factors. Radiopharmaceutical production requires automated or remote synthesis modules that are characterized by their efficiency for incorporating the radiotracer into a radiopharmaceutical and the length of time and the amount of human interaction required. Understanding the principles of PET-CT and the optimal scanning techniques and recognizing the potential pitfalls and limitations are important for advantageous use of this imaging modality.

REFERENCES

1. Francis IR, Brown RKJ, Avram AM. The clinical role of CT/PET in oncology: an update. Cancer Imaging 2005; 5: 68-75.

2. Tressaud A, Haufe G. Fluorine and Health: Molecular Imaging, Biomedical Materials and Pharmaceuticals. Amsterdam: Elsevier Science & Technology; 2008, p. 141-96.

3. Bybel B, Brunken RC, Shah S, Wu G, Turbiner E, Neumann DR. PET and PET/CT imaging: what clinicians need to know. Cleve Clin J Med 2006; 73: 1075-87.

4. Kapoor V, McCook B, Torok F. An introduction to PET-CT imaging. RadioGraphics 2004; 24: 523-43.

5. Demeter S, Applegate KE, Perez M. Internet-based ICRP resource for healthcare providers on the risk and benefits of medical imaging that uses ionizing radiation. Ann ICRP 2016; 45(1): 148-55.

6. Beyer T, Antoch G, Bockisch A, Stattaus J. Optimized Intravenous contrast administration for diagnostic whole-body F18-FDG PET/CT. J Nucl Med 2005; 46: 429-35.

7. Hicks RJ, Ware RE, Lau EWF. PET/CT: will it change the way that we use CT in cancer imaging? Cancer Imaging 2006; 6: 69-79.

8. Schöder H, Yeung HWD, Larson S. CT in PET/CT: essential features of interpretation. J Nucl Med 2005; 46: 1249-51.

9. Shahhosseini S. PET radiopharmaceuticals. Iranian Journal of Pharmaceutical Research 2011; 10(1): 1-2.

10. Vallabhajosula S. 18F-labeled PET radiopharmaceuticals in oncology: an overview of radiochemistry and mechanism of tumor localization. Semin Nucl Med 2007; 37(6): 400-19.

11. Advances in medical radiation imaging for cancer diagnosis and treatment. Nuclear Technology Review, IAEA; 2006, p. 110-27.

12. Peller P, et al. PET-CT and PET-MRI in Oncology, Medical Radiology. Diagnostic Imaging, Springer-Verlag Berlin Heidelberg; 2012: 19-30.

13. Sarji S. Physiological uptake in FDG PET similating disease. Biomed Imaging Interv J 2006; 2(4): 59.

14. Vavere AL, et al. 11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med 2008; 49: 327-34.

15. Jadvar H. Molecular imaging of prostate cancer: PET radiotracers. AJR 2012; 199: 278-91.

16. Pieterman R, et al. Comparison of 11C-choline and 18F-FDG PET in primary diagnosis and staging of patients with thoracic cancer. J Nucl Med 2002; 43: 167-72.

17. Gabriel M, et al. 68Ga-DOTA-Tyr3-Octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48: 508-18.

18. Bauwens M, Chekol R, Vanbilloen H, Bormans G, Verbruggen A. Optimal buffer choice of the radiosynthesis of (68)Ga-Dotatoc for clinical application. Nucl Med Commun 2010; 31(8): 753-8.

19. Wadsak W, Mitterhauser M. Basics and principles of radiopharmaceuticals for PET/CT. Eur J Radiol 2010; 73: 461-9.

20. Avery R, Kuo PH. 18F sodium fluoride PET/CT detects osseous metastases from breast cancer missed on FDG PET/CT with marrow rebound. Clin Nucl Med 2013; 38(9): 746-8.

21. Tehrani OS, Shields AF. PET imaging of proliferation with pyrimidines. J Nucl Med 2013; 54: 903-12.

22. Heiss WD. Clinical impact of amino acid PET in gliomas. J Nucl Med 2014; 55: 1219-20.

23. Zhao Z, Yoshida Y, Kurokawa T, Kiyono Y, Mori T, Okazawa H. 18FFES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis. J Nucl Med 2013; 54(4): 499-506.

24. Bittner MI, et al. Exploratory geographical analysis of hypoxic subvolumes using 18F-MISO-PET imaging in patients with head and neck cancer in the course of primary chemoradiotherapy. Radiother Oncol. 2013; 108(3): 511-6.

25. Weineisen M, et al. 68Ga and 177 Lu-Labeled PSMA I&T: Optimatization of a PSMA-Targeted theranostic concept and first proof-of-concept human studies. J Nucl Med 2015; 56: 1169-76.

26. Kabasakal L, et al. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl Med Commun 2015; 36(6): 582-7.